Sign in

    Mani Furuhar

    Managing Director and Senior Research Analyst at Leerink Partners

    Mani Foroohar, M.D., is a Managing Director and Senior Research Analyst at Leerink Partners specializing in Genetic Medicines within the Therapeutics team. He covers a targeted list of biotech companies, including BridgeBio Pharma and 4D Molecular Therapeutics, achieving an average stock price target met ratio of 57.25% and a documented potential upside of 44.81% across 409 ratings on 27 stocks; his best-performing recommendation generated an 11.19% return in one day on 4D Molecular Therapeutics. Foroohar joined Leerink Partners in 2018 following analyst roles at Aptigon Capital (Citadel), Green Owl Capital Management, and Barclays, and co-founded Cellanyx Diagnostics. He holds an M.D. from Stanford, an M.B.A from Columbia, a B.S. from UCLA, has been a Howard Hughes Medical Institute Research Fellow, and is a FINRA-registered securities professional.

    Mani Furuhar's questions to ARROWHEAD PHARMACEUTICALS (ARWR) leadership

    Mani Furuhar's questions to ARROWHEAD PHARMACEUTICALS (ARWR) leadership • Q3 2025

    Question

    Mani Furuhar's representative asked about the upcoming ARO-INHBE obesity data, specifically which cohorts would be included and what the company hopes to see relative to other muscle-sparing agents.

    Answer

    Management confirmed that data from single-ascending dose, multiple-ascending dose, and combination cohorts will be presented. The data will include various biomarkers, body composition changes measured by MRI, weight loss, and effects on lipid and glycemic parameters.

    Ask Fintool Equity Research AI